Chemotherapy in adult soft tissue sarcoma

Indian Journal of Cancer

Volumn 46, Issue 4, 2009, Pages 274-287

  Jain, A ^a   Sajeevan, K V ^a   Babu, K G ^a   Lakshmaiah, K C ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Adjuvant; Chemotherapy; IGF inhibitors; Metastatic STSs; MTOR inhibitors; Neoadjuvant; Soft tissue sarcoma; Trabectedin; VEGF inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MESNA; PAZOPANIB; PEMETREXED; RAPAMYCIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRABECTEDIN; TROFOSFAMIDE; UNINDEXED DRUG;

ADULT; ANGIOSARCOMA; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMORADIOTHERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SENSITIVITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER DYSFUNCTION; MALIGNANT FIBROUS HISTIOCYTOMA; META ANALYSIS; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SOFT TISSUE SARCOMA; SYSTEMATIC REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 70349413276     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.55547     Document Type: Review

References (62)

1. Benjamin R, Pisters Peter WT, Helman LJ, Bramwell Vivien HC, Rubin BP, O'Sullivan B. Sarcomas of Soft Tissue. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKeena WG,editors. Clinical Oncology: 4th edition. Philadelphia: Churchill Livingstone Elsvier; 2008. p. 2009-2056
2. Casali P.G, Jost L, Sleijfer S, Verweij J, Blay J-Y. Soft tissue sarcoma: ESMO Clinical Recommendations for diagnosis,treatment and follow up. Ann Oncol 2009;20:iv132-6.
3. (National Comprehensive Cancer Network.NCCN Clinical Practice guidelines in Oncology.Soft tissue sarcoma. Available from: http://www.nccn.org/ professionals/physicians-gls/PDF/Soft tissue sarcoma.pdf).
4. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. Highdose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
5. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996;14:2653-2665 (Pubitemid 26329649)
6. Hohenberger P, Wysocki WM. Neoadjuvant Treatment of Locally Advanced Soft Tissue Sarcoma of the Limbs: Which Treatment to Choose? Oncologist 2008;13:175-186
7. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial. Lancet 2002;359:2235-2241
8. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: Preoperative versus postoperative radiotherapy. J Surg Oncol 1996;61:90-99
9. Toma S, Canavese G, Grimaldi A, Ravera G, Ugolini D, Percivale P, et al. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: Experience of the National Cancer Institute of Genoa. Oncol Rep 2003;10:641-647
10. Pisters PW, Patel SR, Prieto VG, Thall PF, Lewis VO, Feig BW, et al. Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas. J Clin Oncol 2004;22:3375-3380
11. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-1127
12. Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG, et al. Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control. Strahlenther Onkol 1999;175:259-266
13. Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, et al. A randomised phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001;37:1096-1103
14. Issels RD, Abdel-Rahman S, Wendtner C, Falk MH, Kurze V, Sauer H, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent highrisk adult soft-tissue sarcomas (STS) of adults: Long-term results of a phase II study. Eur J Cancer 2001;37:1599-1608 (Pubitemid 32778604)
15. Brennan MF, Singer S, Maki R, O'Sullivan. Sarcomas of the Soft Tissue and Bone. In: Devita VT, Lawrence TS, Rosenberg SA, editiors. Cancer Principles and Practice of Oncology: 8th edition. Philadelphia: Lippincott Williams and Wilkins; 2008. p.1741-1794
16. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.Lancet 1997;350:1647-1654
17. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A Systematic Meta-Analysis of Randomized Controlled Trials of Adjuvant Chemotherapy for localized resectable Soft-Tissue Sarcoma. Cancer 2008;113:573-581
18. Woll PJ, Van Glabbeke M,P Hohenberger Le Cesne, A. Gronchi, H. J. Hoekstra, et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in soft tissue sarcoma: Interim analysis of a randomized phase III trial. J Clin Oncol 2007;25:(Abstract 10008)
19. Le Cesne A, Glabbekke VM, Woll PJ, Bramwell VH, Casali PG, Hoekstra HJ, et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimens in resected high grade soft tissue sarcoma(STS): Pooled analysis of the two STBSG-EORTC phase II clinical trials. J Clin Oncol 2008;26:(Abstract 10525).
20. O'Connor JM, Chacon M, F.E Petracci, Chacon RD. Adjuvant chemotherapy in soft tissue sarcoma(STS): A meta-analysis of published data.JCO;26: (Abstract10526).
21. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CyVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545
22. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.J Clin Oncol 1993;11:1269-1275
23. Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, et al. High-dose epirubicin is not an alternative to standarddose doxorubicin in the treatment of advanced soft tissue sarcomas: A study of the EORTC Soft Tissue and Bone Sarcoma Group. Br J Cancer 1998;78:1634-1639
24. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomized phase II trial of pegylated liposomal doxorubicin(DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastastic soft tissue sarcomas: A study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-877
25. Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, et al. Variations in schedules of ifosfamide administration: A better understanding of its implications on pharmacokinetics through a randomized cross-over study. Cancer Chemother Pharmacol 2007;60:375-381
26. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 2007;25:3144-3150
27. Tascilar M, Loos WJ, Seynaeve C, Verweij J, Sleijfer S. The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas. Oncologist 2007;12:1351-1360
28. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M; Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008;34:339-347
29. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285
30. Bui BN, Chevallier B, Chevreau C, Krakowski I, Peny AM, Thyss A, et al. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:2629-2636
31. Verma S, Younus J, Haynes AE, Stys-Norman D, Blackstein M; the members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Dose-intensive chemotherapy with growth factor or autologous bone marrow or stem-cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: A clinical practice guideline. Curr Oncol 2008;15:80-84
32. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489
33. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002;20:2824-2831
34. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. An adaptively randomized phase II study of gemcitabine and docetaxel versus gemcitabine alone in patients with metastatic soft-tissue sarcomas. J Clin Oncol 2007;25:2755-2763
35. Guan Y, Sakai R, Rinehart KL, Wang AH. Molecular and crystalstructures of ecteinascidins: Potentantitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J Biomol Struct Dyn 1993;10:793-818.
36. Carter NJ, Keam SJ. Trabectedin. A review of its use in the management of Soft Tissue Sarcoma and Ovarian Cancer. Drugs 2007;67:2257-2276
37. Schoffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, et al. Trabectedin(ET-743): Evaluation of its use in advanced soft tissue sarcoma. Future Oncol 2007;3:381-392
38. Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, et al. Clinical Impact of trabectedin (ecteniscidin- 743) in advanced/ metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008;9:1609-1618
39. Le Cesne A, Demetri G, Jean L. Impact of Yondelis in the natural history of patients with pretreated advanced soft tissue sarcomas: Long-term follow-up results. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November; Boston, MA, USA: 2003. p. 17-23
40. Morgan JA, Le Cesne A, Chawla S, et al. Randomized Phase II study of trabectedin in patients with liposarcoma and leiomyosarcomas after failure of prior anthracyclines and ifosfamide.Proc Am Soc Clin Oncol 2007. J Clin Oncol 2007;25:(Abstract 10060).
41. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766. Drugs R D 2006;7:317-328
42. Magenau JM, Schuetze SM. New targets for therapy of sarcoma. Curr Opin Oncol 2008;20:400-406
43. Wan X, Helman LJ. The Biology of mTOR Inhibition in Sarcoma. Oncologist 2007;12;1007-1018
44. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006;18:360-362
45. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007;13:748-753
46. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002;100:3767-3775
47. Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas. J Clin Oncol 2006;24:521s. (Abstract 9505).
48. Scotlandi K, Picci P. Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol 2008;20:419-427
49. Kuhnen C, Lehnhardt M, Tolnay E, Muehlberger T, Vogt PM, Muller KM. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J Cancer Res Clin Oncol 2000;126:219-225 (Pubitemid 30183025)
50. Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, et al. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol 2004;130:52-56 (Pubitemid 38161248)
51. Sleijfer S, van der Graaf WT, Blay JY. Angiogenesis Inhibition in Non- GIST Soft Tissue Sarcomas. Oncologist 2008;13:1193-1200
52. Ryan CW, Von Mehren M, Rankin CJ, J. R. Goldblum, G. D. Demetri, V. H. Bramwell, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008;26:S561.(Abstract 10532).
53. Maki RG, Keohan ML, Undevia M, M. Livingston, M. M. Cooney, A. Elias, et al. Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060. J Clin Oncol 2008;26:S560(Abstract 10531)
54. Vigil CE, Chiaporri AA, Williams CA, H. H. Shrager, B. L. Murray, D. G. Letson, et al. Phase II of sunitinib malate (SM) in patients with metastatic soft tissue sarcomas (STS) other than GIST. J Clin Oncol 2008; 26:S560 (Abstract 10535).
55. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a phase II study from the EORTC STBSG (EORTC 62043. J Clin Oncol 2007;25: (Abstract 10031)
56. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549
57. D'Adamo DR, Anderson SE, Albritton K, Yamada J, Riedel E, Scheu K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142 (Pubitemid 46260301)
58. Hartmann JT. Systemic treatment options for the patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs 2007;18:245-254
59. Verweij J. Other Endpoints in Screening Studies for Soft Tissue Sarcomas. Oncologist 2008;13:S27-S31.
60. dos Santos NR, de Bruijn DR, van Kessel AG. Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 2001;30:1-14.
61. Albritton KH, Randall RL. Prospects for Targeted therapy of Synovial Sarcoma. J Pediatr Hematol Oncol 2005;27:219-220
62. Kawaguchi S, Wada T, Ida K, Sato Y, Nagoya S, Tsukahara T, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005;3:1.